Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329719 | 0.88 | CCR2 (0.48) | MEN1KMT2ASLC6A4CCR2 | |
| SCHEMBL7369115 | 0.84 | CCR2 (0.49) | MEN1KMT2ASLC6A4KCNH2CCR2 | |
| SCHEMBL15733769 | 0.84 | OPRD1 (0.63) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL12104025 | 0.81 | OPRM1 (0.63) | OPRM1KMT2A | |
| SCHEMBL5756148 | 0.81 | OPRM1 (0.72) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL8324812 | 0.81 | OPRM1 (0.63) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL5759031 | 0.81 | CCR2 (0.46) | OPRM1MEN1KMT2ASLC6A4CCR2 | |
| SCHEMBL5761230 | 0.80 | APP (0.52) | OPRM1MEN1KMT2AOPRD1SLC22A1 | |
| SCHEMBL18390231 | 0.80 | HSD11B1 (0.51) | MEN1KMT2A | |
| SCHEMBL11560742 | 0.78 | OPRD1 (0.52) | OPRM1KMT2AOPRD1SLC6A4OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441718-B1 | USE OF CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | ENDO PHARMACEUTICALS, INC., A DELAWARE CORPORATION (US) | 2005-02-03 | — | — | US | disclosed |
| US-6825217-B2 | HETEROCYCLIC AMINES SUCH AS 4-(3'-THIENYL)-ALPHA, ALPHA, 1-TRIMETHYL-4-PIPERIDINEMETHANOL AND/OR PRODRUGS, USED AS ANALGESICS FOR PROPHYLAXIS OF NEUROPATHIC PAIN | ENDO PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | ENDO PHARMACEUTICALS INC. | 2003-08-28 | — | — | US | disclosed |
| EP-0337167-B1 | 4-Aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof | DU PONT MERCK PHARMA (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5086063-A | Analgesics, antidepressants, anorexigenic agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-02-04 | — | — | US | disclosed |
| US-5019650-A | 4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-28 | — | — | US | disclosed |
| EP-0337167-A1 | 4-Aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | CNR2, CNR1, OPRL1 | OPRM1 11/4885MEN1 4044/4885KMT2A 3676/4885 |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | PMP22, NAT1, MAG | OPRM1 227/4885MEN1 1395/4885KMT2A 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.